Literature DB >> 20688896

Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae.

Yuriz Bakhtiar1, Hirofumi Hirano, Kazunori Arita, Shunji Yunoue, Shingo Fujio, Atsushi Tominaga, Tetsuhiko Sakoguchi, Kazuhiko Sugiyama, Kaoru Kurisu, Junko Yasufuku-Takano, Koji Takano.   

Abstract

OBJECTIVE: Somatotropinomae are classified as densely and sparsely granulated adenomae, which typically exhibit a perinuclear pattern (PP) and a dot pattern (DP) in cytokeratin (CK) immunostaining respectively. Some exhibit a mixed pattern (MP). We studied the relationship between these somatotropinoma subtypes and their clinico-pathological features.
METHODS: The study population consisted of 141 Japanese acromegalic patients. We evaluated their clinical presentation and their response to provocation tests with TRH and LHRH and to suppression (octreotide) test. Tumour tissues were subjected to immunostaining for CAM-5.2, MIB-1, CD34, E-cadherin (CDH1) and p53 (TP53). In 43 cases (30 non-DP and 13 DP), we analysed gsp mutations (constitutively activating mutations of the G(s)α protein that is encoded by GNAS gene).
RESULTS: The 141 adenomae were categorised into three subtypes based on their CK staining patterns; 30 (21.3%) exhibited DP, 83 (58.9%) exhibited PP, and 28 (19.9%) exhibited MP. Compared with the other subtypes, DP adenomae were significantly larger, and their E-cadherin expression and response to TRH, LHRH and octreotide challenge were lower. The postoperative cure rate tended to be lower in DP adenomae. gsp mutations were detected in 25 of 43 cases examined (58.1%); 20 of the 30 non-DP (66.7%) and 5 of the 13 DP tumours (38.5%) were affected by the mutation.
CONCLUSION: DP somatotropinomae exhibit characteristic features. Compared with the non-DP subtypes, DP adenomae manifested a larger tumour size, a lower incidence of abnormal responses to TRH and LHRH challenge, a poor response to octreotide test and a lower expression of E-cadherin. gsp mutation was not exclusive for non-DP somatotropinomae.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688896     DOI: 10.1530/EJE-10-0586

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  33 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

2.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

3.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

Review 4.  Clinical implications of growth hormone-secreting tumor subtypes.

Authors:  Katja Kiseljak-Vassiliades; Shibana Shafi; Janice M Kerr; Tzu L Phang; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

Review 5.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

7.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

8.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

9.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 10.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.